vs
Esperion Therapeutics, Inc.（ESPR）与ZIPRECRUITER, INC.（ZIP）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是ZIPRECRUITER, INC.的1.5倍（$168.4M vs $111.7M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 0.6%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -4.4%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
ZipRecruiter, Inc.是一家美国线上招聘平台企业，主打面向求职者与招聘方的求职招聘匹配服务，为双方提供高效对接的人才服务市场，帮助求职者快速找到适配岗位，也助力企业高效完成招聘需求。
ESPR vs ZIP — 直观对比
营收规模更大
ESPR
是对方的1.5倍
$111.7M
营收增速更快
ESPR
高出143.1%
0.6%
两年增速更快
ESPR
近两年复合增速
-4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $111.7M |
| 净利润 | — | $-835.0K |
| 毛利率 | — | 89.1% |
| 营业利润率 | 50.6% | 3.6% |
| 净利率 | — | -0.7% |
| 营收同比 | 143.7% | 0.6% |
| 净利润同比 | — | 92.3% |
| 每股收益（稀释后） | $0.32 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRZIP
| Q4 25 | $168.4M | $111.7M | ||
| Q3 25 | $87.3M | $115.0M | ||
| Q2 25 | $82.4M | $112.2M | ||
| Q1 25 | $65.0M | $110.1M | ||
| Q4 24 | $69.1M | $111.0M | ||
| Q3 24 | $51.6M | $117.1M | ||
| Q2 24 | $73.8M | $123.7M | ||
| Q1 24 | $137.7M | $122.2M |
净利润ESPRZIP
| Q4 25 | — | $-835.0K | ||
| Q3 25 | $-31.3M | $-9.8M | ||
| Q2 25 | $-12.7M | $-9.5M | ||
| Q1 25 | $-40.5M | $-12.8M | ||
| Q4 24 | — | $-10.8M | ||
| Q3 24 | $-29.5M | $-2.6M | ||
| Q2 24 | $-61.9M | $7.0M | ||
| Q1 24 | $61.0M | $-6.5M |
毛利率ESPRZIP
| Q4 25 | — | 89.1% | ||
| Q3 25 | — | 89.1% | ||
| Q2 25 | — | 89.3% | ||
| Q1 25 | — | 89.4% | ||
| Q4 24 | — | 89.6% | ||
| Q3 24 | — | 89.4% | ||
| Q2 24 | — | 89.5% | ||
| Q1 24 | — | 89.1% |
营业利润率ESPRZIP
| Q4 25 | 50.6% | 3.6% | ||
| Q3 25 | -11.4% | -4.4% | ||
| Q2 25 | 8.6% | -5.9% | ||
| Q1 25 | -34.0% | -10.6% | ||
| Q4 24 | -6.4% | -3.6% | ||
| Q3 24 | -31.0% | -2.8% | ||
| Q2 24 | 3.5% | 7.6% | ||
| Q1 24 | 52.5% | -0.7% |
净利率ESPRZIP
| Q4 25 | — | -0.7% | ||
| Q3 25 | -35.9% | -8.5% | ||
| Q2 25 | -15.4% | -8.5% | ||
| Q1 25 | -62.2% | -11.7% | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | -57.2% | -2.2% | ||
| Q2 24 | -83.9% | 5.7% | ||
| Q1 24 | 44.3% | -5.3% |
每股收益（稀释后）ESPRZIP
| Q4 25 | $0.32 | $-0.03 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $-0.10 | ||
| Q1 25 | $-0.21 | $-0.13 | ||
| Q4 24 | $-0.14 | $-0.10 | ||
| Q3 24 | $-0.15 | $-0.03 | ||
| Q2 24 | $-0.33 | $0.07 | ||
| Q1 24 | $0.34 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $188.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $-77.2M |
| 总资产 | $465.9M | $569.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRZIP
| Q4 25 | $167.9M | $188.0M | ||
| Q3 25 | $92.4M | $211.8M | ||
| Q2 25 | $86.1M | $203.5M | ||
| Q1 25 | $114.6M | $221.1M | ||
| Q4 24 | $144.8M | $218.4M | ||
| Q3 24 | $144.7M | $225.6M | ||
| Q2 24 | $189.3M | $271.7M | ||
| Q1 24 | $226.6M | $282.5M |
股东权益ESPRZIP
| Q4 25 | $-302.0M | $-77.2M | ||
| Q3 25 | $-451.4M | $-76.1M | ||
| Q2 25 | $-433.5M | $-65.9M | ||
| Q1 25 | $-426.2M | $-11.3M | ||
| Q4 24 | $-388.7M | $13.4M | ||
| Q3 24 | $-370.2M | $13.6M | ||
| Q2 24 | $-344.2M | $24.4M | ||
| Q1 24 | $-294.3M | $12.7M |
总资产ESPRZIP
| Q4 25 | $465.9M | $569.7M | ||
| Q3 25 | $364.0M | $573.6M | ||
| Q2 25 | $347.1M | $592.4M | ||
| Q1 25 | $324.0M | $629.4M | ||
| Q4 24 | $343.8M | $664.1M | ||
| Q3 24 | $314.1M | $652.0M | ||
| Q2 24 | $352.3M | $665.3M | ||
| Q1 24 | $373.1M | $662.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $7.7M |
| 自由现金流经营现金流 - 资本支出 | — | $7.6M |
| 自由现金流率自由现金流/营收 | — | 6.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $9.9M |
8季度趋势，按日历期对齐
经营现金流ESPRZIP
| Q4 25 | $45.2M | $7.7M | ||
| Q3 25 | $-4.3M | $2.6M | ||
| Q2 25 | $-31.4M | $10.5M | ||
| Q1 25 | $-22.6M | $-9.9M | ||
| Q4 24 | $-35.0M | $12.5M | ||
| Q3 24 | $-35.3M | $9.3M | ||
| Q2 24 | $-7.2M | $21.9M | ||
| Q1 24 | $53.8M | $2.0M |
自由现金流ESPRZIP
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $-10.2M | ||
| Q4 24 | — | $12.0M | ||
| Q3 24 | $-35.5M | $9.2M | ||
| Q2 24 | $-7.3M | $21.7M | ||
| Q1 24 | $53.8M | $1.9M |
自由现金流率ESPRZIP
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 9.1% | ||
| Q1 25 | — | -9.3% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | -68.7% | 7.8% | ||
| Q2 24 | -9.9% | 17.6% | ||
| Q1 24 | 39.0% | 1.6% |
资本支出强度ESPRZIP
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 0.2% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.1% |
现金转化率ESPRZIP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
ZIP
| License | $84.3M | 75% |
| Services | $27.4M | 25% |
